A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

Merck's Vaxneuvance – formerly known as V114 – is the first major competition to Pfizer's franchise in the big market for conjugate pneumococcal vaccines ... with its off-label use.

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based .

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

It's a companion shot to Merck's Vaxneuvance (formerly V114), which covers 15 serotypes and was approved by the FDA last year as a rival to Pfizer's Prevnar 13 and newer Prevnar 20 vaccines ...

This year, pharmaceutical giant Merck (NYSE: MRK ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

Merck will face an important patent cliff by ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the company has a deep pipeline, with more than 80 programs in phase 2 studies ...